Ascent Group LLC Acquires Shares of 646 Insulet Corporation $PODD

Ascent Group LLC acquired a new stake in Insulet Corporation (NASDAQ:PODD) in the second quarter, Holdings Channel reports. The fund acquired 646 shares of the medical instruments supplier’s stock, valued at approximately $203,000.

A number of other hedge funds have also recently added to or reduced their stakes in PODD. Wealth Enhancement Advisory Services LLC grew its stake in Insulet by 16.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 2,658 shares of the medical instruments supplier’s stock valued at $694,000 after acquiring an additional 384 shares during the period. Merit Financial Group LLC acquired a new stake in Insulet in the first quarter valued at approximately $209,000. Wedmont Private Capital boosted its position in shares of Insulet by 26.2% during the first quarter. Wedmont Private Capital now owns 1,804 shares of the medical instruments supplier’s stock valued at $458,000 after buying an additional 374 shares during the last quarter. OLD National Bancorp IN boosted its position in shares of Insulet by 6.7% during the first quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier’s stock valued at $231,000 after buying an additional 55 shares during the last quarter. Finally, Portside Wealth Group LLC boosted its position in shares of Insulet by 10.8% during the first quarter. Portside Wealth Group LLC now owns 1,118 shares of the medical instruments supplier’s stock valued at $294,000 after buying an additional 109 shares during the last quarter.

Insulet Stock Performance

Shares of PODD opened at $315.49 on Thursday. The firm has a market cap of $22.21 billion, a PE ratio of 95.89, a PEG ratio of 2.60 and a beta of 1.40. The stock’s fifty day moving average price is $322.51 and its two-hundred day moving average price is $299.51. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet Corporation has a 1 year low of $225.37 and a 1 year high of $353.50.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business’s revenue was up 32.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the business’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a research report on Wednesday. The Goldman Sachs Group cut their target price on Insulet from $399.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Truist Financial assumed coverage on Insulet in a research report on Monday, June 16th. They set a “buy” rating and a $365.00 target price on the stock. Royal Bank Of Canada lifted their target price on Insulet from $330.00 to $350.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Finally, Piper Sandler boosted their price objective on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $346.83.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.